NASDAQ: VERA - Vera Therapeutics, Inc.

Yield per half year: -7.3%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Vera Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., биотехнологическая компания клинической стадии, занимается разработкой и коммерциализацией лечения пациентов с серьезными иммунологическими заболеваниями. Его ведущим продуктом-кандидатом является атацицепт, гибридный белок, который вводится самостоятельно в виде подкожной инъекции, который находится в фазе IIb клинических испытаний для пациентов с нефропатией иммуноглобулина А; и для лечения волчаночного нефрита. Он также разрабатывает MAU868, моноклональное антитело для лечения инфекций, вызываемых виремией BK. Ранее компания называлась Trucode Gene Repair, Inc.

more details
и сменила название на Vera Therapeutics, Inc. в апреле 2020 года. Vera Therapeutics, Inc. была зарегистрирована в 2016 году, ее штаб-квартира находится в Брисбене, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-05-14
ISIN US92337R1014
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://veratx.com
Цена ао 34.77
Change price per day: 0% (33.92)
Change price per week: +1.65% (33.37)
Change price per month: -20.09% (42.45)
Change price per 3 month: -28.35% (47.34)
Change price per half year: -7.3% (36.59)
Change price per year: +0.8323% (33.64)
Change price per 3 year: +77.87% (19.07)
Change price per 5 year: 0% (33.92)
Change price per 10 year: 0% (33.92)
Change price per year to date: -30% (48.46)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 6.71 1
P/E 0 0
EV/EBITDA -6.65 0
Total: 2.38

Efficiency

Title Value Grade
ROA, % -54.68 0
ROE, % -94.4 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.7143 7.14
Total: 1.17

Debt

Title Value Grade
Debt/EBITDA -0.5036 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 824.69 10
Yield EPS, % -22.71 0
Total: 6
More

ETF Share, % Profitability for 1 year, % Dividends, %
Virtus LifeSci Biotech Clinical Trials ETF 0.90613 63.04 0.33
Direxion Daily S&P Biotech Bull 3x Shares 0.41379 4067.92 0.25924
Future Tech ETF 0.22702 426.34 0.8416
Principal Healthcare Innovators ETF 0.22702 618.5 0.8416
Invesco Nasdaq Biotechnology ETF 0.22131 28.58 0.8565
Vanguard U.S. Momentum Factor ETF 0.16 30.05 1.05834
ProShares Ultra Nasdaq Biotechnology 0.14648 51.7 0.85651
Nuveen ESG Small-Cap ETF 0.14545 13.91 1.41019
VictoryShares US Small Mid Cap Value Momentum ETF 0.14394 36.19 1.97666
iShares Russell 2000 Growth ETF 0.12375 38.04 0.6026
Vanguard Russell 2000 Growth ETF 0.11 23.05 0.60264
JPMorgan BetaBuilders U.S. Small Cap Equity Fund 0.10183 24.75 1.59225
iShares Morningstar Small-Cap Growth ETF 0.06755 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.06755 587.89 0.72598
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.05233 31.36 1.41955
iShares ESG Aware MSCI USA Small-Cap ETF 0.05116 18.09 1.49366
Vanguard Russell 2000 ETF 0.05 17.16 1.48801
Schwab U.S. Small-Cap ETF 0.04859 17.47 1.51433
ProShares UltraPro Russell2000 0.03602 89.82 1.47873
iShares Morningstar Small-Cap ETF 0.03388 391.25 1.60498
iShares Morningstar Small-Cap ETF 0.03388 30.1 1.60498
Fidelity MSCI Health Care Index ETF 0.02134 3 1.46057
Humankind US Stock ETF 0.01166 18.81 1.99919
ProShares Hedge Replication ETF 0.00955 5.92 1.47892
Schwab U.S. Broad Market ETF 0.00318 24.86 1.43354
iShares Russell 3000 ETF 0.00309 24.83 1.43482
Dimensional US Core Equity Market ETF 0.00074 30.98 1.40618
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Mr. Sean P. Grant M.B.A. Chief Financial Officer 585.5k 1985 (40 years)
Mr. Joseph R. Young M.B.A. Senior VP of Finance & Chief Accounting Officer N/A 1973 (52 years)
Mr. Julien E. Capers J.D. Senior Vice President of Legal N/A
Ms. Kelly Rauber Senior Vice President of Human Resources N/A
Mr. Tom Doan Senior Vice President of Development Operations N/A 1972 (53 years)
Dr. Neeraj Pakala M.B.A., Ph.D. Senior VP and Head of Product Development & Manufacturing N/A
Dr. Kerry Cooper M.D. Senior Vice President of Medical Affairs N/A
Dr. Marshall W. Fordyce M.D. Founder, President, CEO & Director 1975 (50 years)
Mr. David L. Johnson M.B.A. Chief Opearating Officer
Ms. Lauren Frenz M.B.A. Chief Business Officer 1985 (40 years)

Address: United States, Brisbane. CA, 8000 Marina Boulevard - open in Google maps, open in Yandex maps
Website: https://veratx.com